Ex vivo cell labeling with 64Cu–pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography

We have used copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (64Cu–PTSM) to radiolabel cells ex vivo for in vivo positron-emission tomography (PET) imaging studies of cell trafficking in mice and for eventual application in patients. 2-[18F]-Fluoro-2-deoxy-d-glucose (FDG) cell labeling also was evaluated for comparison. 64Cu–PTSM uptake by C6 rat glioma (C6) cells increased for 180 min and then stabilized. The labeling efficiency was directly proportional to 64Cu–PTSM concentration and influenced negatively by serum. Label uptake per cell was greater with 64Cu–PTSM than with FDG. However, both 64Cu–PTSM- and FDG-labeled cells showed efflux of cell activity into supernatant. The 64Cu–PTSM labeling procedure did not interfere significantly with C6 cell viability and proliferation rate. MicroPET images of living mice indicate that tail-vein-injected labeled C6 cells traffic to the lungs and liver. In addition, transient splenic accumulation of radioactivity was clearly detectable in a mouse scanned at 3.33 h postinfusion of 64Cu–PTSM-labeled lymphocytes. In contrast, the liver was the principal organ of tracer localization after tail-vein administration of 64Cu–PTSM alone. These results indicate that in vivo imaging of cell trafficking is possible with 64Cu–PTSM-labeled cells. Given the longer t1/2 of 64Cu (12.7 h) relative to 18F (110 min), longer cell-tracking periods (up to 24–36 h) should be possible now with PET.

[1]  R Weissleder,et al.  Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. , 2001, Journal of immunological methods.

[2]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Lewis,et al.  Copper radionuclides and radiopharmaceuticals in nuclear medicine. , 1996, Nuclear medicine and biology.

[4]  W. Oyen,et al.  Imaging infection/inflammation in the new millennium , 2001, European Journal of Nuclear Medicine.

[5]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[6]  S. Bergmann,et al.  Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  T. Irimura,et al.  Real-time PET analysis of metastatic tumor cell trafficking in vivo and its relation to adhesion properties. , 1995, Biochimica et biophysica acta.

[8]  U. Nannmark,et al.  Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals , 2000, Cancer Immunology, Immunotherapy.

[9]  S. Cherry,et al.  Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  R. Leahy,et al.  High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. , 1998, Physics in medicine and biology.

[11]  R K Jain,et al.  A method for labeling cells for positron emission tomography (PET) studies. , 1994, Journal of immunological methods.

[12]  T. Irimura,et al.  Tumor cells with organ-specific metastatic ability show distinctive trafficking in vivo: analyses by positron emission tomography and bioimaging. , 1997, Cancer research.

[13]  S. Cherry,et al.  Simultaneous PET and MR imaging , 1997, Physics in medicine and biology.

[14]  T Irimura,et al.  Positron emission tomography analysis of metastatic tumor cell trafficking. , 1994, Cancer research.